02882nam 2200817z- 450 991055711450332120231214133626.0(CKB)5400000000040901(oapen)https://directory.doabooks.org/handle/20.500.12854/69079(EXLCZ)99540000000004090120202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierOutcomes and Therapeutic Management of Bladder CancerBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 electronic resource (120 p.)3-03936-934-2 3-03936-935-0 Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.Medicinebicsscbladder cancerrobotic-assistedopenradical cystectomysurvivalpropensity scoreageurothelial carcinomaoutcomeanesthesia recovery periodscognitive impairmentgamma-cyclodextrinsneuromuscular blockaderobotic radical cystectomyglycogenclear-cell adenocarcinomaurinary bladderSEER program databasefemaleintracorporeal neobladderoutcomesroboticsex-sparingmethylationbiomarkersFOXA1GATA3KRT20molecular markersmRNAmuscle-invasive bladder cancerPCRhuman epidermal growth factor receptor 2indoleamine 2,3-dioxygenaseprogrammed death ligand-1immunotherapynodal diseasepN1neoadjuvantadjuvantchemotherapyMedicineMoschini Marcoedt481847Moschini MarcoothBOOK9910557114503321Outcomes and Therapeutic Management of Bladder Cancer3038144UNINA